Charles Henderson

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Walter M. Stadler, Robert A. Figlin, David F. McDermott et al. · Cancer · 2010 · 253 citations

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium

Manish A. Shah, Yelena Y. Janjigian, Ronald G. Stoller et al. · Journal of Clinical Oncology · 2015 · 176 citations

Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy

Charles L. Vogel, Ronald Yanagihara, Albert J. Wood et al. · The Oncologist · 2004 · 76 citations · Full text

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

Shanu Modi, Cristina Saura, Charles Henderson et al. · Breast Cancer Research and Treatment · 2013 · 69 citations · Full text